Valuation : Theravance Inc

Market Cap 1.52B 1.31B 1.24B 1.13B 2.12B 145B 2.13B 14.61B 5.69B 73.52B 5.72B 5.59B 244B P/E 2026 *
9.8x
P/E 2027 * 9.05x
Enterprise Value 1.09B 941M 885M 806M 1.52B 104B 1.52B 10.47B 4.07B 52.67B 4.1B 4.01B 175B EV / Sales 2026 *
2.44x
EV / Sales 2027 * 1.83x
Free-Float
98.99%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 42 2020-05-19
Director of Finance/CFO 60 2023-08-20
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 75 2018-02-11
Director/Board Member 66 2018-02-11
Director/Board Member 42 2025-05-18
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%-5.97%+58.34%+108.22% 1,031B
+2.01%-0.71%+53.07%+68.99% 641B
+1.39%-2.18%+23.57%+75.43% 453B
-1.50%-7.04%+33.55%+33.94% 349B
+6.25%+2.04%+28.97%+46.57% 290B
-0.07%-4.12%+0.95%+11.79% 252B
+1.92%-0.93%+52.28%+70.67% 232B
+0.51%-4.52%-19.50%-54.83% 201B
+2.45%+0.77%+32.71%+95.59% 181B
Average +1.62%-2.91%+29.33%+50.71% 403.31B
Weighted average by Cap. +1.60%-3.40%+38.39%+66.40%

Financials

2026 *2027 *
Net sales 447M 385M 362M 330M 621M 42.38B 624M 4.28B 1.67B 21.56B 1.68B 1.64B 71.48B 489M 422M 397M 361M 679M 46.38B 683M 4.69B 1.82B 23.59B 1.83B 1.79B 78.22B
Net income 175M 151M 142M 130M 244M 16.63B 245M 1.68B 654M 8.46B 658M 644M 28.05B 183M 158M 149M 136M 255M 17.4B 256M 1.76B 685M 8.85B 688M 674M 29.35B
Net Debt -432M -373M -350M -319M -600M -41B -604M -4.14B -1.61B -20.85B -1.62B -1.59B -69.15B -631M -544M -512M -466M -877M -59.87B -882M -6.05B -2.36B -30.45B -2.37B -2.32B -101B
Logo Theravance Inc
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, it is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. Its products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO, is for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in a Phase III clinical trial.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-